Ozempic (semaglutide) prior authorization denied appeal
GLP-1 for type 2 diabetes
Typical PA criteria
- Type 2 diabetes diagnosis (ICD-10 E11.x)
- A1C above plan threshold (commonly 7.0)
- Trial of metformin
Why your PA was denied
- Off-label use for weight loss
- Step therapy with metformin not documented
- Missing A1C results
- Quantity limit exceeded
Evidence that overturns the denial
- ✓ICD-10 E11.x in chart
- ✓Recent A1C result
- ✓Metformin trial history with dose and duration
- ✓Letter of medical necessity citing SUSTAIN trial data
Denials for off-label weight-loss use rarely overturn. For diabetes use, ensure the diagnosis code is on every claim.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Ozempic (semaglutide) prior authorization denied?+
The most common reasons are: Off-label use for weight loss; Step therapy with metformin not documented; Missing A1C results. Your denial letter names the specific criteria you did not meet.
How do I appeal a Ozempic (semaglutide) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Ozempic (semaglutide) denial?+
ICD-10 E11.x in chart; Recent A1C result; Metformin trial history with dose and duration.
What if the plan excludes Ozempic (semaglutide) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)
- Humira (adalimumab)